Core Insights - NeOnc Technologies Holdings, Inc. has officially incorporated NuroMENA Holdings Ltd. in Abu Dhabi, completing a $50 million cornerstone investment led by Quazar Investment [3][4][6] - This partnership aims to launch NeOnc's CNS platform in the MENA region and accelerate the development of its therapeutic pipeline, including NEO212 and NEO100 programs [4][5] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on therapies for CNS cancers, with a strong intellectual property portfolio and academic collaborations [7] - Quazar Investment is a strategic investment firm managing over $3.3 billion in assets, focusing on transformative investments in biotechnology and healthcare across the MENA region [8] Strategic Partnership - The incorporation of NuroMENA is seen as a significant validation of NeOnc's global vision and commitment to delivering innovative therapies [5] - Quazar Investment will have majority control of NuroMENA, facilitating joint governance and strategic alignment to enhance CNS therapies in the region [6][7]